Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers
Open Access
- 28 June 2010
- journal article
- Published by BMJ in Journal of Medical Genetics
- Vol. 47 (9), 579-585
- https://doi.org/10.1136/jmg.2010.077677
Abstract
Background Reported prevalence, penetrance and expression of deleterious mutations in the mismatch repair (MMR) genes, MLH1, MSH2, MSH6 and PMS2, may reflect differences in the clinical criteria used to select families for DNA testing. The authors have previously reported that clinical criteria are not sensitive enough to identify MMR mutation carriers among incident colorectal cancer cases. Objective To describe the sensitivity of the criteria when applied to families with a demonstrated MMR mutation. Methods Families with an aggregation of colorectal cancers were examined for deleterious MMR mutations according to the Mallorca guidelines. All families with a detected MMR mutation as of November 2009 were reclassified according to the Amsterdam and Bethesda criteria. Results Sixty-nine different DNA variants were identified in a total of 129 families. The original Amsterdam clinical criteria were met by 38%, 12%, 78% and 25% of families with mutations in MSH2, MSH6, MLH1 and PMS2, respectively. Corresponding numbers for the revised Amsterdam criteria were 62%, 48%, 87% and 38%. Similarly, each of the four clinical Bethesda criteria had low sensitivity for identifying MSH6 or PMS2 mutations. Conclusion Amsterdam criteria and each of the Bethesda criteria were inadequate for identifying MSH6 mutation-carrying kindreds. MSH6 mutations may be more common than currently assumed, and the penetrance/expression of MSH6 mutations, as derived from families meeting current clinical criteria, may be misleading. To increase detection rate of MMR mutation carriers, all cancers in the Lynch syndrome tumour spectrum should be subjected to immunohistochemical analysis and/or analysis for microsatellite instability.Keywords
This publication has 31 references indexed in Scilit:
- Risks of Lynch Syndrome Cancers for MSH6 Mutation CarriersJNCI Journal of the National Cancer Institute, 2010
- Performance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based studyBritish Journal of Cancer, 2010
- Recommendations to improve identification of hereditary and familial colorectal cancer in EuropeFamilial Cancer, 2009
- Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate CancerCancer Epidemiology, Biomarkers & Prevention, 2009
- Awareness of heredity in colorectal cancer patients is insufficient among clinicians: a Norwegian population‐based studyColorectal Disease, 2009
- A homozygote splice site PMS2 mutation as cause of Turcot syndrome gives rise to two different abnormal transcriptsFamilial Cancer, 2008
- Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome populationFamilial Cancer, 2008
- Origins and Prevalence of the American Founder Mutation of MSH2Cancer Research, 2008
- A new variant database for mismatch repair genes associated with Lynch syndromeHuman Mutation, 2007
- Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)Journal of Medical Genetics, 2007